<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="correction" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2022.11170</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-11170</article-id>
<article-categories>
<subj-group>
<subject>Correction</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>RNA-binding protein CELF2 inhibits breast cancer cell invasion and angiogenesis by downregulating NFATc1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Limin</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Xie</surname><given-names>Xiju</given-names></name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<month>03</month>
<year>2022</year></pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>01</month>
<year>2022</year></pub-date>
<volume>23</volume>
<issue>3</issue>
<elocation-id>245</elocation-id>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhou et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
</article-meta>
</front>
<body>
<p>Exp Ther Med 22:<related-article id="RA1" related-article-type="corrected-article" vol="22" ext-link-type="doi" xlink:href="10.3892/etm.2021.10330">Article no. 898</related-article>, 2021; DOI: 10.3892/etm.2021.10330</p>
<p>Subsequently to the publication of the above article, an interested reader drew to the authors&#x2019; attention that an error was made during the compilation of <xref rid="f2-ETM-0-0-11170" ref-type="fig">Fig. 2</xref>. Specifically, in <xref rid="f2-ETM-0-0-11170" ref-type="fig">Fig. 2A</xref>, the same image for the mice (accurately presented for the &#x2018;OverExp-CELF2&#x2019; experiment) was inadverently chosen to also represent the &#x2018;Con&#x2019; experiment.</p>
<p>The authors have re-examined their raw data and identified the data that should have been included in the figure. The corrected version of <xref rid="f2-ETM-0-0-11170" ref-type="fig">Fig. 2</xref> is shown on the next page, now including the correct data for the &#x2018;Con&#x2019; experiment in <xref rid="f2-ETM-0-0-11170" ref-type="fig">Fig. 2A</xref>. Note that this error did not have a major impact on either the overall results or on the conclusions reported in this study. The authors regret the error that was made during the assembly of <xref rid="f2-ETM-0-0-11170" ref-type="fig">Fig. 2</xref>, and apologize to the readership for any inconvenience caused.</p>
</body>
<floats-group>
<fig id="f2-ETM-0-0-11170" position="float">
<label>Figure 2</label>
<caption><p>CELF2 overexpression inhibits tumor growth and angiogenesis. (A) Mice and tumor in the three groups. (B) Mouse weight changed from day 0 to day 21. <sup>&#x002A;&#x002A;&#x002A;</sup>P&lt;0.001 vs. Con group. <sup>&#x0023;&#x0023;</sup>P&lt;0.01 and <sup>&#x0023;&#x0023;&#x0023;</sup>P&lt;0.001 vs. NC group. (C) Tumor volume changed from day 0 to day 21. <sup>&#x002A;&#x002A;</sup>P&lt;0.01 and <sup>&#x002A;&#x002A;&#x002A;</sup>P&lt;0.001 vs. Con group. <sup>&#x0023;</sup>P&lt;0.05 and <sup>&#x0023;&#x0023;&#x0023;</sup>P&lt;0.001 vs. NC group. (D) Tumor weight at day 21. <sup>&#x002A;&#x002A;&#x002A;</sup>P&lt;0.001 vs. Con group. <sup>&#x0023;&#x0023;&#x0023;</sup>P&lt;0.001 vs. NC group. (E) Tumor volume at day 21. <sup>&#x002A;&#x002A;&#x002A;</sup>P&lt;0.001 vs. Con group. <sup>&#x0023;&#x0023;&#x0023;</sup>P&lt;0.001 vs. NC group. (F) Angiogenesis was analyzed by HUVEC tube formation assay; scale bar, 100 &#x00B5;m. (G) Western blot analysis was performed to detect the expression of proteins associated with invasion and angiogenesis and NFATc1 in tumor tissues. <sup>&#x002A;&#x002A;</sup>P&lt;0.01 and <sup>&#x002A;&#x002A;&#x002A;</sup>P&lt;0.001 vs. Con group. <sup>&#x0023;&#x0023;</sup>P&lt;0.01 and <sup>&#x0023;&#x0023;&#x0023;</sup>P&lt;0.001 vs. NC group. CELF2, CUGBP Elav-like family member 2; NFATc1, nuclear factor of activated T cells 1; Con, control; NC, negative control.</p></caption>
<graphic xlink:href="etm-23-03-11170-g00.tif" />
</fig>
</floats-group>
</article>
